Nika Beamon set out on a journey, and 26 doctors, 37 procedures and more than 17 years later, a rheumatologist finally ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

With autoimmune pancreatitis linked to a higher cancer risk, doctors must use comprehensive imaging to avoid unnecessary ...

In rheumatology, there is always more to learn — even when it comes to the most well-trod topics and commonly researched ...

Analysts are still pretty upbeat about Amgen’s future. Out of 30 surveyed, the stock earns a “Strong Buy” consensus rating. The average price target is $321.73, which suggests upside of about 15.5% ...

More standardized research is needed to guide second-line agent selection in IgG4-RD. Rituximab offers a highly effective steroid-sparing option for the treatment of immunoglobulin G4-related disease ...

A key phase 3 readout in immune thrombocytopenia is due later this year, along with phase 2 results in asthma, IgG4-related disease, and warm autoimmune haemolytic anaemia, and phase 3 testing in ...

The FDA is currently reviewing the drug as a treatment for immunoglobulin G4-related disease (IgG4-RD), another rare disease that causes inflammation and fibrosis around the body, with a decision ...